Virtual Library

Start Your Search

J. Osawa



Author of

  • +

    P1.07 - Poster Session 1 - Surgery (ID 184)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Surgery
    • Presentations: 1
    • +

      P1.07-037 - Clinical characteristics of completely resected lung cancer with combined pulmonary fibrosis and emphysema (ID 2525)

      09:30 - 09:30  |  Author(s): J. Osawa

      • Abstract

      Background
      The occurrence of both emphysema and pulmonary fibrosis in the same patient has received increased attention as the syndrome of combined pulmonary fibrosis and emphysema (CPFE). Patients with CPFE show severely impaired DLCO, hypoxemia at exercise, characteristic computed tomography (CT) imaging feature, and high probability of lung cancer. However, the clinical characteristics of lung cancer patients with CPFE are not well known. The aim of this study is to identify clinical characteristics of completely resected lung cancer with CPFE.

      Methods
      A total of 559 consecutive patients who underwent complete surgical resection for lung cancer from January 2008 through December 2010 were reviewed. Based on preoperative chest HRCT findings, patients were categorized into three groups: those with normal lung (N) (except for lung cancer), emphysema without pulmonary fibrosis (E), and CPFE. The HRCT inclusion criteria of CPFE is as follows; 1) Presence of emphysema, defined as well-demarcated areas of decreased attenuation in comparison with contiguous normal lung and marginated by a very thin or no wall, and/or multiple bullae with upper zone predominance. 2) Presence of a diffuse parenchymal lung disease with significant pulmonary fibrosis, defined as reticular opacities with peripheral and basal predominance, honeycombing, architectural distortion and/or traction bronchiectasis or bronchiolectasis. Chest HRCT scans were reviewed separately by two thoracic surgeons and one radiologist. The clinical characteristics of patients with CPFE were compared with those of the other groups.

      Results
      This study cohort included 328 (58.7%) patients in N group, 136 (24.8%) patients in E group, and 95 (17.0%) patient in CPFE group, with median age of 67 years. The 3-year survival rates were 68.4% in CPFE group, 80.2% in E group, and 89.7% in N group (p < 0.001). CPFE group found a positive correlation with each of the following factors compared to N and E groups; > 67 years (p = 0.004), lymph node metastases (p = 0.033), male gender (p < 0.001), tumor size > 3cm (p < 0.001), vascular invasion (p < 0.001), non-adenocarcinoma (p < 0.001), pleural invasion (p < 0.001), elevated preoperative serum CEA level (p < 0.001). The frequency of patients presenting grade 2 or more severe postoperative complication under CTCAE or Clavien-Dindo classification was 28.4% for CPFE group, 24.3% for E group, and 14.9% for N group (p = 0.004), and respiratory complication was higher for CPFE group (22.1%) than N group (5.8%) and E group (11.8%) (p < 0.001).

      Conclusion
      Resected lung cancer patients with CPFE had some different clinical characteristics in comparison with those with emphysema. Intensive postoperative management and a strict follow-up are required because of higher rate of postoperative complications and aggressive malignant behavior in CPFE patients.

  • +

    P2.10 - Poster Session 2 - Chemotherapy (ID 207)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Medical Oncology
    • Presentations: 1
    • +

      P2.10-048 - Therapeutic efficacy of gefitinib for postoperative recurrent cancer in patient with EGFR mutation (ID 3134)

      09:30 - 09:30  |  Author(s): J. Osawa

      • Abstract

      Background
      Epidermal growth factor receptor (EGFR) -tyrosine kinase inhibitor (TKI) responds to approximately 80% of the non-small cell lung cancer (NSCLC) patients with EGFR mutation. In other words, about 20% of the patients with EGFR mutations don’t respond. It was reported that resistance to EGFR-TKI is caused by secondary mutation at codon 790 (exon 20 mutation), Met amplification and hepatocyte growth factor (HGF)-MET signaling. The aim of this study is to explore the type of EGFR mutation, phosphorylated MET and HGF expression in tissues surgically removed for NSCLC with EGFR mutation impact on the sensitivity to gefitinib.

      Methods
      We studied 44 surgically resected NSCLC from 2001 to 2012. 43 cases were adenocarcinoma and 1 case was large cell neuroendocrine carcinoma. These surgical resections were taken from patients who were treated with gefitinib as first or second or third line therapy for postoperative recurrent cancer. The patients’ age ranged from 27 to 78years old (average 63.1 years old). There were 19 male and 25 female patients. There was 1 case of exon 18 point mutation, 23 cases of exon 19 deletion, 2 cases of exon 20 point mutation, 16 cases of exon 21 point mutation, and 2 cases of both exon 20 and 21 point mutation. We assessed non-responders progression within 2 months. Intermediate responders were considered as being effectively treated (at least stable disease) with gefitinib between 3 and 11 months. And long-term responders were considered to be effectively treated with gefitinib for over 12 months.

      Results
      Non-responders were 4 cases. Intermediate responders were 26 cases (including 11 cases of ongoing treatment). Long-term responders were 14 cases (including 1 case of ongoing treatment). Non-responders had two secondary mutation, one exon 19 deletion and exon 21 mutation. Intermediate responders had one exon 18 mutation, 14 exon 19 deletion, 10 exon 21 mutation and one both exon 20 and 21 mutation. long-term responder had eight exon 19 deletion, five exon 21 mutation and one both exon 20 and 21 mutation.

      Conclusion
      In our data, NSCLC with exon 20 mutaiton will respond to gefitinib if this NCCLC with another EGFR mutation. We will report the findings of non-responders excluding analyzed exon 20 mutation phosphorylated MET and HGF expression.